RECEIVED
CENTRAL FAX CENTER
SEP 17 2008

In the Claims:

Claims 1-45 and 54-56 are cancelled. Claims 46-50 are allowed. Please amend Claims 51-53 and 57, and renumber claims 61-63 to 62-64, respectively, all as shown below.

1-45. Cancelled

46. (Allowed) A compound having the formula:



or a pharmaceutically acceptable salt thereof, where R^1= –COOH; R^2 = –$(CH_2)_2$-COOH; R^3= H; X= – $(CH_2)_3$–.

47. (Allowed) A compound having the formula:



where the compound is (2S, 3'S, 8'R, 11'S) 2-{[(3'-Amino-1'-aza -2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid, or a pharmaceutically acceptable salt thereof.

48. (Allowed) The compound of Claim 47, where said salt of said compound is (2S, 3'S, 8'R, 11'S) 2-{[(3'-Amino-1'-aza-2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate.

49. (Allowed) A compound having the formula:



where the compound is (2S, 3'S, 8'S, 11'S)-2-{[3'-Amino-1'-aza-2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]-amino}-1,5-pentanedioic acid, or a pharmaceutically acceptable salt thereof.

50. (Allowed) The compound of Claim 49, where said salt of said compound is (2S, 3'S, 8'S, 11'S)-2-{[3'-Amino-1'-aza-2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]-amino}-1,5-pentanedioic acid trifluoroacetate.

51. (Currently amended) A method of treating a mammal to protect neurons ~~otherwise destined to degenerate or die~~ from degenerating as a result of having a hypoxic or ischemic an injury or disease, comprising administering to a patient an effective amount of a compound of Claim 47.

52. (Currently amended) The method of Claim 51, wherein the hypoxic or ischemic injury or disease is a result of one or more conditions selected from the group consisting of head injury, traumatic brain injury, stroke, ischemic injury, hypoxic injury, reperfusion injury, cardiac artery bypass graft surgery, toxin damage, radiation damage and asphyxia.

53. (Currently amended) The method of claim 51, further comprising administering another agent selected from the group consisting of insulin-like growth factor-I [IGF-I], insulin-like growth factor-II [IGF-II], transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding protein, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, ~~karatinocyte~~ keratinocyte growth factor 2, glial-activating factor, FGF-10 and FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 [BMP-2], glial-cell line derived neurotrophic factor, activity-dependant neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α- interferon, β- interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-

phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue [ORG 2766], dizolcipine [MK-801], selegiline, a glutamate antagonist selected from the group consisting of NPS1506, GV1505260, MK-801 and GV150526, an AMPA antagonist selected from the group consisting of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070 and LY300164 and an anti-inflammatory agent selected from the group consisting of anti-MAdCAM-1 antibody and an antibody against an integrin $\alpha 4\beta 1$ receptor and an integrin $\alpha 4\beta 7$ receptor.

54-56. Cancelled.

57. (Currently amended) The method of claim ~~56~~ 53 wherein said anti-MAdCAM-1 antibody is MECA-367.

58. (Previously presented) The method of Claim 51, in which the amount is in the range of about 0.001 mg/kg to about 100 mg/kg mass of said mammal.

59. (Previously presented) The method of Claim 51, wherein said administration is via the cerebrospinal fluid and said amount is in the range of about 0.001 mg/kg to about 0.1 mg/kg mass of said mammal.

60. (Previously presented) The method of Claim 51, wherein said administration is via oral, systemic or parenteral route and said amount is in the range of about 1 mg/kg to about 100 mg/kg mass of said mammal.

61. (Previously presented) The method of Claim 51, wherein said mammal is a human being.

~~61~~ 62. (Previously presented) The method of Claim 51, wherein said compound is administered in a pharmaceutically acceptable solution.

~~62~~ 63. (Previously presented) The method of claim 51, wherein said compound is administered into a lateral cerebral ventricle.

~~63~~ 64. (Previously presented) The method of Claim 51, wherein said compound is administered in a solution having a concentration of compound in the range of about 0.0001 % by weight to about 10% by weight.